Thomas Bachelot

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Sibylle Loibl, Fabrice André, Thomas Bachelot et al. · Annals of Oncology · 2023 · 844 citations · Full text

Medicine, Oncology, Breast Oncology +13

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Nancy U. Lin, Virginia F. Borges, Carey K. Anders et al. · Journal of Clinical Oncology · 2020 · 549 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos et al. · The Lancet Oncology · 2019 · 477 citations

Medicine, Oncology, Pharmacology +14

Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period

Fabrice André, Khémaies Slimane, Thomas Bachelot et al. · Journal of Clinical Oncology · 2004 · 396 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Hope S. Rugo, Florence Lerebours, Eva Ciruelos et al. · The Lancet Oncology · 2021 · 349 citations

Medicine, Oncology, Pharmacology +17